PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis
Fang Wang,1,* Feng-Hua Wang,2,3,* Kaiyu Sun,4,* Chang Jiang,2,5 Sui Peng,6 Li-Xia Xu,1 Ming Kuang,7 Gui-Fang Guo,2,5,8 Shu-Ling Chen9 1Department of Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China; 2State Key Labor...
Saved in:
Main Authors: | Wang F (Author), Wang FH (Author), Sun K (Author), Jiang C (Author), Peng S (Author), Xu LX (Author), Kuang M (Author), Guo GF (Author), Chen SL (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Endoscopic Ultrasound-Guided Biliary Drainage for Unresectable Hilar Malignant Biliary Obstruction
by: Yousuke Nakai, et al.
Published: (2019) -
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021) -
Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
by: Ruijia Chen, et al.
Published: (2022) -
Changing Trends in Biliary Stenting for Unresectable Malignant Perihilar Obstructions
by: Lubna Kamani, et al.
Published: (2020) -
Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
by: Zhuo-miao Ye, et al.
Published: (2023)